2020 / 05

Следующая статья
DOI: 10.24075/vrgmu.2020.063

КЛИНИЧЕСКИЙ СЛУЧАЙ

Применение лазерной коагуляции сетчатки при болезни Илза

Х. П. Тахчиди, Н. Х. Тахчиди, Т. А. Касмынина, Е. П. Тебина, М. В. Мокрунова
Информация об авторах

Российский национальный исследовательский медицинский университет имени Н. И. Пирогова, Москва, Россия

Для корреспонденции: Екатерина Павловна Тебина
Волоколамское шоссе, д. 30, корп. 2, г. Москва, 123182; ur.liam@anibetaniretake

Информация о статье

Вклад авторов: Х. П. Тахчиди — концепция и дизайн исследования, редактирование текста; Е. Х. Тахчиди — анализ литературных данных; Е. П. Тебина — написание текста; Т. А. Касмынина — лазерное лечение пациента; М. В. Мокрунова — сбор и обработка материала.

Статья получена: 20.09.2020 Статья принята к печати: 12.10.2020 Опубликовано online: 23.10.2020
|
  1. Therese KL, Deepa P, Therese J, Bagyalakshmi R, Biswas J, Madhavan HN. Asso-ciation of mycobacteria with Eales’ disease. Indian J Med Res. 2007; 126: 56–62.
  2. Yannuzzi LA. The Retinal Atlas. Retinal Vascular Diseases, Eales’ Disease. Elsevier. 2010: 433–8.
  3. Das T, Pathengay A, Hussain N, Biswas J. Eales’ disease: diagnosis and management. Eye. 2010; 24 (3): 472–82.
  4. Eales H. Retinal haemorrhages associated with epistaxis and constipation. Brim Med. 1880; 9: 262.
  5. Madhavan HN, Therese KL, Doraiswamy K. Further investigations on the association of Mycobacterium tuberculosis with Eales' disease. Indian J Ophthalmol. 2002; 50: 35–39.
  6. Patwardhan SD, Azad E, Shah BM, Sharma Y. Role of intravitreal bevacizumab in Eales disease with dense vitreous haemorrhage: a prospective randomized control study. Retina. 2011; 31 (5): 866–70.
  7. Biswas J, K R R, Pal B, Gondhale HP, Kharel Sitaula R. Long- Term Outcomes of a Large Cohort of Patients with Eales' Disease. Ocul Immunol Inflamm. 2018; 26 (6): 870–6.
  8. Sen A, Paine SK, Chowdhury IH, Mukherjee A, Choudhury S, Mandal LK, Bhattacharya B. Assessment of gelatinase and tumor necrosis factor-alpha level in the vitreous and serum of patients with Eales disease; role of inflammation-mediated angio-genesis in the pathogenesis of Eales disease. Retina. 2011; 31 (7): 1412–20.
  9. Saxena S, Kumar D. Macular involvement in Eales disease. Ann Ophthalmol. 2000; 32 (2): 98–100.
  10. Gupta V, Al-Dhibi HA, Arevalo JF. Retinal imaging in uveitis. Saudi J Ophthalmol. 2014; 28: 95–103.
  11. Kumar V, Chandra P, Kumar A. Ultra-wide field angiography in the management of Eales disease. Indian J Ophthalmol. 2016; 64: 504–7.
  12. Mwndoza KA, Lauer A. Eales Disease. American Academy of Ophthalmology. 2015. Available from: http://eyewiki.org/Eales_ Disease.
  13. Saxena S, Kumar D. New classification system-based visual outcome in Eales’disease. Indian J Ophthalmol. 2007; 55 (4): 267–9.
  14. Biswas J, Ravi RK, Naryanasamy A, Kulandai LT, Madhavan HN. Eales’ disease — current concepts in diagnosis and management. J Ophthalmic Inflamm Infect. 2013; 3: 11.
  15. Das TP, Namperumalsamy P. Photocoagulation in Eales’ disease. Results of pro-spective randomised clinical study. Presented in XXVI Int Cong Ophthalmol – Singapore, 1990.
  16. Ishaq M, Niazi MK. Usefulness of laser photocoagulation in managing asymptomatic eyes of Eales disease. J Ayub Med Coll Abbottabad. 2002; 14 (4): 22–25.
  17. Ishaq M, Feroze AH, Shahid M, Baig MA, Ameen SS, Feroze SH, Chishti RA. Intravitreal steroids may facilitate treatment of Eales' disease (idiopathic retinal vasculitis): an interventional case series. Eye (Lond). 2007; 21: 1403–5.
  18. Kumar A, Sinha S. Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab. Can J Ophthalmol. 2007; 42 (2): 335–6.
  19. Magargal LE, Walsh AW, Magargal HO, et al. Treatment of Eales’ disease with scat-ter laser photocoagulation. Ann Ophthalmol. 1989; 21: 300–2.
  20. Talat L, Lightman S, Tomkins-netzer O. Ischemic retinal vasculitis and its manage-ment. J Ophthalmol. 2014; 2014: 197675.
  21. Li J, Liu SM, Dong WT, Li F, Zhou CH, Xu XD, Zhong J. Outcomes of transconjunctival sutureless 27-gauge vitrectomy for vitreoretinal diseases. Int J Ophthalmol. 2018; 11 (3): 408–15.
  22. El-Asrar AM, Al-Kharashi SA. Full panretinal photocoagulation and early vitrectomy improve prognosis of retinal vasculitis associated with tuberculoprotein hypersensitivity (Eales' disease). Br J Ophthalmol. 2002; 86 (11): 1248–51.
  23. Dehghan MH, Ahmadieh H, Soheilian M, Azarmina M, Mashayekhi A, Naghibozakerin J. Therapeutic effects of laser photocoagulation and/or vitrectomy in Eales' disease. Eur J Ophthalmol. 2005; 15 (3): 379–83.
  24. Gopal L, Abraham C. Efficacy of photocoagulation in Eales’ disease. Trans Asia-Pacific Acad. 1985; 10: 689.
  25. Nada M, Qanoongo S, Singh SV, Khurana AK. A rare presentation of exudative macroaneurysms in unilateral Eales' disease. Nepal J Ophthalmol. 2017; 9 (18): 95–98.
  26. Murphy RP, Gieser SC, Fine SL, et al. Retinal and vitreous findings in Eales disease. Invest Ophthalmol Vis Sci. 1986; 27: 121.
  27. Nicolcescu A, Mocanu C, Dinu L, Olaru A, Ionete M, Stefanescu DA. Unilateral Eales' disease a case report. Rom J Ophthalmol. 2017; 61 (2): 144–9.
  28. Педанова Е. К., Буряков Д. А. Эффективность лазеркоагуляции при болезни Илза в свете современных представлений об этиопатогенезе заболевания. Современные технологии лечения витреоретинальной патологии — 2013. 2013: 136. Доступно по ссылке: https://eyepress.ru/article.aspx?12646.
  29. Толстухина Е. А., Магарамов Д. А., Володин П. Л., Тимохов В. Л., aФомин А. В. Лазер-индуцированный регресс периферической ретинальной неоваскуляризации при болезни Илза (клинический случай). Современные технологии в офтальмологии. 2019; 1 (26): 381–3.
  30. Mainster MA. Decreasing retinal photocoagulation damage: principles and techniques. Semin Ophthalmol. 1999; 14 (4): 200–9.
  31. Moutray T, Evans JR, Lois N, Armstrong DJ, Peto T, Azuara- Blanco A. Different lasers and techniques for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2018; 3 (3): CD012314.
  32. Reddy SV, Husain D. Panretinal Photocoagulation: A Review of Complications. Semin Ophthalmol. 2018; 33 (1): 83–88.